CAN ALZHEIMER'S BE DETECTED THROUGH A BLOOD TEST?

Blood tests for Alzheimer’s disease are becoming one of the most significant developments in dementia research. Scientists are now developing blood based tests that can identify proteins linked to Alzheimer’s disease, raising hopes that diagnosis may eventually become quicker, simpler, and less invasive.

At the moment, there is no single blood test that can definitively diagnose Alzheimer’s disease on its own in routine UK healthcare. However, newer biomarker blood tests are showing promising accuracy when used alongside memory assessments, brain scans, symptoms, and medical history.

Researchers believe these tests could eventually improve early diagnosis, help people access treatment sooner, and reduce the need for more invasive procedures such as lumbar punctures.

For many years, diagnosing Alzheimer’s disease has relied on a combination of memory testing, brain scans, specialist assessments, and sometimes spinal fluid testing. This process can take time and may not always be easily accessible for every patient.

New blood tests are changing that landscape by offering a simpler way to look for biological changes linked to Alzheimer’s disease. Researchers are developing tests that measure specific biomarkers associated with the condition, particularly abnormal amyloid and tau proteins.

This has become increasingly important because many people living with dementia never receive a confirmed diagnosis explaining the underlying cause of their symptoms. Alzheimer’s disease is responsible for around 60% to 80% of dementia cases, meaning earlier and more accurate identification could make a major difference to patient care and treatment planning.

Although the research is progressing rapidly, blood tests are not currently used as standalone diagnostic tools within routine NHS care. Doctors still need to interpret results alongside cognitive assessments, symptoms, medications, and wider medical history.

Alzheimer’s blood tests look for biomarkers, which are measurable biological signs associated with disease.

The main focus is on amyloid and tau proteins. In Alzheimer’s disease, these proteins build up abnormally in the brain and interfere with normal brain function. Amyloid proteins can form plaques around brain cells, while tau proteins can form tangles inside brain cells. Both are strongly associated with Alzheimer’s disease progression.

Researchers have discovered that traces of these abnormal proteins may also become measurable in the bloodstream. This has led to the development of tests such as pTau181 and pTau217, which are designed to estimate the likelihood that Alzheimer’s related changes are occurring within the brain.

These blood tests do not directly “see” Alzheimer’s disease itself. Instead, they help doctors assess how likely it is that the biological changes associated with Alzheimer’s are present.

Current evidence suggests that pTau181 may be especially useful for helping rule out Alzheimer’s disease when results are negative, while pTau217 appears particularly effective for identifying patients who are more likely to have Alzheimer’s disease. Researchers are still studying how these tests should best be used together in clinical practice.

One of the reasons these tests have generated so much attention is their level of accuracy in research studies.

According to Johns Hopkins Medicine, some newer blood tests can predict the likelihood of amyloid plaque buildup with more than 90% accuracy in certain patient groups. Research has also shown that pTau181 has a very strong negative predictive value, meaning a negative result makes Alzheimer’s disease much less likely. Meanwhile, pTau217 appears to have a stronger positive predictive value, making it particularly useful for identifying patients more likely to have Alzheimer’s disease.

Despite these promising results, no blood test is perfect. Around one in five patients may fall into an “intermediate” category where results are not completely clear and further assessment is still required. In these situations, doctors may recommend additional investigations such as PET scans, lumbar puncture testing, or specialist neurological assessment.

This is why blood test results still need interpretation by specialists rather than being viewed in isolation.

At present, Alzheimer’s blood tests are mainly intended for people who are already experiencing symptoms of cognitive decline rather than healthy people without symptoms.

This may include individuals experiencing memory problems, confusion, difficulty concentrating, or challenges managing everyday tasks. According to current research and FDA cleared guidance in the United States, some tests are designed for adults aged 55 and older who have already undergone medical assessment for cognitive decline.

Importantly, these tests are not currently designed as general screening tools for the wider population. There is a major difference between investigating existing symptoms and attempting to predict future Alzheimer’s disease risk in healthy individuals.

For now, blood biomarker testing is primarily focused on helping doctors investigate current cognitive symptoms more accurately.

In the UK, Alzheimer’s blood tests are currently more commonly available through research studies or private healthcare settings rather than standard NHS services.

One of the most important UK initiatives is the Blood Biomarker Challenge, a project involving Alzheimer’s Society, Alzheimer’s Research UK, and the National Institute for Health and Care Research. The project aims to evaluate how dementia blood testing could eventually be introduced safely and effectively into the NHS.

Researchers are investigating how accurate these tests are in real world clinical settings and whether they perform consistently across different patient populations, including different ages, ethnicities, and sexes.

More evidence is still needed before widespread NHS rollout can happen. For now, NHS dementia diagnosis continues to rely on broader clinical assessment rather than blood testing alone.

There is currently no single test that can diagnose dementia by itself. Instead, doctors build a diagnosis using several different assessments together.

The process often begins with a GP appointment, where the doctor may ask about symptoms, daily functioning, medical history, medications, mood, and changes noticed by family members. Simple cognitive assessments may then be used to evaluate memory, concentration, language, and thinking ability.

Routine blood tests are also commonly used to check for other possible causes of memory symptoms. If concerns remain, patients may be referred to a specialist memory clinic for more detailed assessment.

Brain scans such as MRI or CT scans may also be used to help identify patterns linked to dementia or rule out other conditions such as stroke or brain tumours. However, scans alone cannot diagnose dementia in isolation. Doctors must interpret all findings together to understand the overall clinical picture.

Although new Alzheimer’s biomarker testing is exciting, standard blood tests remain a very important part of dementia investigations.

Many medical conditions can cause symptoms that resemble memory or thinking problems. Doctors may therefore check for issues such as vitamin B12 deficiency, thyroid dysfunction, diabetes, liver disease, kidney disease, or infection.

In some cases, these conditions may be treatable, and memory symptoms may improve once the underlying problem is addressed. This is one reason why it is important not to assume memory problems automatically mean Alzheimer’s disease.

Early assessment can help identify both treatable medical conditions and cases where further dementia investigation is needed.

Researchers are strongly focused on earlier detection because identifying Alzheimer’s disease sooner may provide important benefits for both patients and families.

An earlier diagnosis may help people understand symptoms sooner, access support earlier, plan for the future, and potentially participate in clinical trials for emerging treatments. It may also reduce uncertainty for family members trying to understand behavioural or memory changes.

Blood testing could also improve accessibility because it is generally much simpler and less invasive than PET scans or lumbar punctures. Researchers believe earlier detection will become even more important as treatments designed to slow Alzheimer’s progression continue to develop.

Despite the progress being made, Alzheimer’s blood tests still have limitations.

Firstly, they cannot currently replace full clinical assessment. Dementia includes several different diseases, and not all forms can be identified using the same biomarkers. Blood tests therefore need to be interpreted alongside symptoms, cognitive assessments, medical history, medications, and sometimes brain imaging.

Research is also evolving rapidly, and experts are still working to determine the best way to use these tests within routine healthcare systems. Over the next few years, dementia diagnosis pathways may change significantly as both testing and treatments continue to advance.

For now, blood testing should be viewed as an important new tool that may support diagnosis rather than completely replace existing assessment methods.

If memory problems are persistent, worsening, or affecting everyday life, it is important to seek medical advice.

Symptoms worth discussing with a doctor may include increasing short term memory problems, repeatedly asking the same questions, getting lost in familiar places, struggling to find words, or difficulty managing daily tasks.

In many cases, family members or close friends notice changes before the individual themselves does. It is also important to remember that memory problems can have many different causes, including stress, anxiety, depression, vitamin deficiencies, and other medical conditions.

Seeking assessment early may help identify treatable causes or allow earlier support where dementia is present.